288:
514:
306:
34:
27:
301:
361:
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (April 2005). "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort".
535:
398:"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study"
307:
Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health
Initiative
530:
47:
266:= Oral estrogen plus progesterone was not analyzed because there was a low number of women who used this therapy.
227:
149:
86:
445:
Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N (June 2014).
69:
51:
476:
427:
378:
343:
326:
Mirkin S (August 2018). "Evidence on the use of progesterone in menopausal hormone therapy".
302:
Template:Risk of breast cancer with menopausal hormone therapy in large observational studies
466:
458:
417:
409:
370:
335:
471:
446:
422:
397:
231:
175:
524:
43:
447:"Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort"
65:
339:
462:
413:
480:
431:
382:
347:
282:
374:
396:
Fournier A, Berrino F, Clavel-Chapelon F (January 2008).
507:
499:
495:
492:Editors can experiment in this template's sandbox
28:
8:
70:
35:
21:
15:
470:
421:
536:Templates that generate named references
250: <5 years
235: <5 years
202: <2 years
179: <2 years
153: <2 years
128: <2 years
109: <2 years
90: <2 years
318:
261:
64:
61:
58:
206: 4–6 years
204: 2–4 years
183: 4–6 years
181: 2–4 years
157: 4–6 years
155: 2–4 years
130: 2–4 years
111: 2–4 years
92: 2–4 years
16:
252: ≥5 years
237: ≥5 years
208: ≥6 years
185: ≥6 years
159: ≥6 years
132: ≥4 years
113: ≥4 years
94: ≥4 years
7:
107:Transdermal estrogen plus progestin
14:
286:
248:Estrogen plus other progestogens
223:E3N-EPIC: Fournier et al. (2014)
200:Estrogen plus other progestogens
145:E3N-EPIC: Fournier et al. (2008)
82:E3N-EPIC: Fournier et al. (2005)
1:
340:10.1080/13697137.2018.1455657
126:Oral estrogen plus progestin
75:Tooltip confidence interval
552:
491:
85:Transdermal estrogen plus
48:menopausal hormone therapy
515:Subpages of this template
463:10.1007/s10549-014-2934-6
414:10.1007/s10549-007-9523-x
262:
222:
144:
81:
451:Breast Cancer Res. Treat
402:Breast Cancer Res. Treat
291:Template documentation
52:observational studies
50:by duration in large
531:Medication templates
55:
375:10.1002/ijc.20710
281:
280:
258:2.02 (1.81–2.26)
243:1.31 (1.15–1.48)
218:1.95 (1.62–2.35)
195:1.32 (0.93–1.86)
169:1.22 (0.89–1.67)
543:
511:
503:
485:
484:
474:
442:
436:
435:
425:
393:
387:
386:
358:
352:
351:
323:
292:
290:
289:
256:1.70 (1.50–1.91)
241:1.13 (0.99–1.29)
216:1.79 (1.44–2.23)
214:1.59 (1.30–1.94)
212:1.36 (1.07–1.72)
193:1.28 (0.83–1.99)
191:1.16 (0.79–1.71)
189:0.84 (0.51–1.38)
167:1.26 (0.87–1.82)
165:0.95 (0.67–1.36)
163:0.71 (0.44–1.14)
76:
72:
56:
37:
30:
23:
551:
550:
546:
545:
544:
542:
541:
540:
521:
520:
519:
518:
513:
505:
493:
490:
489:
488:
444:
443:
439:
395:
394:
390:
360:
359:
355:
325:
324:
320:
315:
298:
293:
287:
285:
257:
255:
251:
249:
242:
240:
236:
234:
226:Estrogens plus
217:
215:
213:
211:
207:
205:
203:
201:
194:
192:
190:
188:
184:
182:
180:
178:
168:
166:
164:
162:
158:
156:
154:
152:
139:
137:
135:
131:
129:
127:
120:
118:
116:
112:
110:
108:
101:
99:
97:
93:
91:
89:
74:
54:(Mirkin, 2018)
41:
12:
11:
5:
549:
547:
539:
538:
533:
523:
522:
504:and testcases
487:
486:
437:
388:
363:Int. J. Cancer
353:
334:(4): 346–354.
317:
316:
314:
311:
310:
309:
304:
297:
294:
284:
283:
279:
278:
260:
259:
253:
245:
244:
238:
232:dydrogesterone
224:
220:
219:
209:
197:
196:
186:
176:dydrogesterone
174:Estrogen plus
171:
170:
160:
148:Estrogen plus
146:
142:
141:
140:1.9 (1.2–3.2)
133:
123:
122:
121:1.2 (0.8–1.7)
114:
104:
103:
102:1.2 (0.7–2.0)
95:
83:
79:
78:
63:
60:
40:
39:
32:
25:
17:
13:
10:
9:
6:
4:
3:
2:
548:
537:
534:
532:
529:
528:
526:
516:
509:
501:
497:
482:
478:
473:
468:
464:
460:
457:(2): 535–43.
456:
452:
448:
441:
438:
433:
429:
424:
419:
415:
411:
408:(1): 103–11.
407:
403:
399:
392:
389:
384:
380:
376:
372:
369:(3): 448–54.
368:
364:
357:
354:
349:
345:
341:
337:
333:
329:
322:
319:
312:
308:
305:
303:
300:
299:
295:
276:
273:
269:
265:
254:
247:
246:
239:
233:
229:
225:
221:
210:
199:
198:
187:
177:
173:
172:
161:
151:
147:
143:
138:1.6 (1.1–2.3)
136:1.2 (0.9–1.8)
134:
125:
124:
119:1.4 (1.0–1.8)
117:1.6 (1.3–2.0)
115:
106:
105:
100:0.7 (0.4–1.2)
98:0.9 (0.6–1.4)
96:
88:
84:
80:
73:
67:
57:
53:
49:
45:
44:breast cancer
38:
33:
31:
26:
24:
19:
18:
454:
450:
440:
405:
401:
391:
366:
362:
356:
331:
327:
321:
274:
271:
267:
263:
228:progesterone
150:progesterone
87:progesterone
66:Hazard ratio
20:
328:Climacteric
525:Categories
313:References
275:Additional
264:Footnotes:
481:24781971
432:17333341
383:15551359
348:29630427
296:See also
42:Risk of
498:|
472:5924370
423:2211383
268:Sources
62:Therapy
512:pages.
508:create
500:mirror
496:create
479:
469:
430:
420:
381:
346:
272:Main:
68:(95%
59:Study
46:with
477:PMID
428:PMID
379:PMID
344:PMID
467:PMC
459:doi
455:145
418:PMC
410:doi
406:107
371:doi
367:114
336:doi
277::
230:or
527::
475:.
465:.
453:.
449:.
426:.
416:.
404:.
400:.
377:.
365:.
342:.
332:21
330:.
270::
77:)
71:CI
517:.
510:)
506:(
502:)
494:(
483:.
461::
434:.
412::
385:.
373::
350:.
338::
36:e
29:t
22:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.